Potential Autoimmunity Resulting from Molecular Mimicry between SARS-CoV-2 Spike and Human Proteins

SARS-CoV-2 causes COVID-19, a disease curiously resulting in varied symptoms and outcomes, ranging from asymptomatic to fatal. Autoimmunity due to cross-reacting antibodies resulting from molecular mimicry between viral antigens and host proteins may provide an explanation. We computationally investigated molecular mimicry between SARS-CoV-2 Spike and known epitopes. We discovered molecular mimicry hotspots in Spike and highlight two examples with tentative autoimmune potential and implications for understanding COVID-19 complications. We show that a TQLPP motif in Spike and thrombopoietin shares similar antibody binding properties. Antibodies cross-reacting with thrombopoietin may induce thrombocytopenia, a condition observed in COVID-19 patients. Another motif, ELDKY, is shared in multiple human proteins such as PRKG1 and tropomyosin. Antibodies cross-reacting with PRKG1 and tropomyosin may cause known COVID-19 complications such as blood-clotting disorders and cardiac disease, respectively. Our findings illuminate COVID-19 pathogenesis and highlight the importance of considering autoimmune potential when developing therapeutic interventions to reduce adverse reactions.

[1]  Bjoern Peters,et al.  Bioinformatic Analysis Underpinning the Frequent Occurrence of Immune Thrombocytopenic Purpura in COVID-19 Patients. , 2022, The Israel Medical Association journal : IMAJ.

[2]  G. Narasimhan,et al.  EMoMiS: A Pipeline for Epitope-based Molecular Mimicry Search in Protein Structures with Applications to SARS-CoV-2 , 2022, bioRxiv.

[3]  Benjamin Bowe,et al.  Long-term cardiovascular outcomes of COVID-19 , 2022, Nature Medicine.

[4]  Bjoern Peters,et al.  Lack of evidence of significant homology of SARS-CoV-2 spike sequences to myocarditis-associated antigens , 2022, eBioMedicine.

[5]  K. Khunti,et al.  Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection , 2021, Nature Medicine.

[6]  P. Desprès,et al.  The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMINARTY vaccine (Pfizer/BioNTech) , 2021 .

[7]  M. Takeda Proteolytic activation of SARS‐CoV‐2 spike protein , 2021, Microbiology and immunology.

[8]  Bosco K. Ho,et al.  SARS‐CoV‐2 structural coverage map reveals viral protein assembly, mimicry, and hijacking mechanisms , 2021, Molecular systems biology.

[9]  V. Khavinson,et al.  Homology between SARS CoV-2 and human proteins , 2021, Scientific Reports.

[10]  A. Galvani,et al.  Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis , 2021, Proceedings of the National Academy of Sciences.

[11]  M. Beltramello,et al.  Broad betacoronavirus neutralization by a stem helix–specific human antibody , 2021, Science.

[12]  K. Kavukcuoglu,et al.  Highly accurate protein structure prediction for the human proteome , 2021, Nature.

[13]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[14]  Paul J. Birrell,et al.  Anti-spike antibody response to natural SARS-CoV-2 infection in the general population , 2021, medRxiv.

[15]  S. Li,et al.  Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern , 2021, JCI insight.

[16]  R. Selvarangan,et al.  Cross-reactive antibody immunity against SARS-CoV-2 in children and adults , 2021, Cellular & Molecular Immunology.

[17]  M. Salvi,et al.  Protein kinase CK2: a potential therapeutic target for diverse human diseases , 2021, Signal Transduction and Targeted Therapy.

[18]  Jared G. Galloway,et al.  Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs , 2021, Cell Reports.

[19]  Fridtjof Lund-Johansen,et al.  Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination , 2021, The New England journal of medicine.

[20]  Andreas Greinacher,et al.  Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination , 2021, The New England journal of medicine.

[21]  Christian C Toquica Gahona,et al.  Secondary Immune Thrombocytopenic Purpura Triggered by COVID-19 , 2021, Cureus.

[22]  M. Tarantino,et al.  Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine , 2021, Journal of blood medicine.

[23]  Chaok Seok,et al.  Structure, Dynamics, Receptor Binding, and Antibody Binding of the Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein in a Viral Membrane , 2021, Journal of chemical theory and computation.

[24]  R. Pinapati,et al.  Immunoreactive peptide maps of SARS-CoV-2 , 2021, Communications biology.

[25]  D. Ho,et al.  Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite , 2021, bioRxiv.

[26]  Minoru Kanehisa,et al.  KEGG: integrating viruses and cellular organisms , 2020, Nucleic Acids Res..

[27]  Limin Wang,et al.  Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis , 2020, BMC Infectious Diseases.

[28]  M. Ghany,et al.  Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care , 2020, Hepatology.

[29]  Elizabeth B White,et al.  Diverse Functional Autoantibodies in Patients with COVID-19 , 2020, Nature.

[30]  Yu Hu,et al.  Thrombocytopenia and thrombosis in hospitalized patients with COVID-19 , 2020, Journal of Hematology & Oncology.

[31]  Q. Ye,et al.  Kidney involvement in COVID‐19 and its treatments , 2020, Journal of medical virology.

[32]  Chaok Seok,et al.  Structure, Dynamics, Receptor Binding, and Antibody Binding of Fully-glycosylated Full-length SARS-CoV-2 Spike Protein in a Viral Membrane , 2020, bioRxiv.

[33]  D. Lewis,et al.  COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives , 2020, Nature Reviews Cardiology.

[34]  D. Kanduc From Anti-SARS-CoV-2 Immune Responses to COVID-19 via Molecular Mimicry , 2020, Antibodies.

[35]  Andrew R. Leach,et al.  The Global Phosphorylation Landscape of SARS-CoV-2 Infection , 2020, Cell.

[36]  J. Tate,et al.  Loss of Taste and Smell as Distinguishing Symptoms of Coronavirus Disease 2019 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  A. Sette,et al.  The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients , 2020, Science Immunology.

[38]  Y. Li,et al.  Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[39]  L. Samaranayake,et al.  Loss of taste and smell , 2020, British Dental Journal.

[40]  Nathan R Kern,et al.  Developing a Fully-glycosylated Full-length SARS-CoV-2 Spike Protein Model in a Viral Membrane , 2020, bioRxiv.

[41]  Shaun Rawson,et al.  Distinct conformational states of SARS-CoV-2 spike protein , 2020, Science.

[42]  Fang Li,et al.  Cell entry mechanisms of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.

[43]  W. Brady,et al.  Cardiovascular complications in COVID-19 , 2020, The American Journal of Emergency Medicine.

[44]  Yuan Yu,et al.  Thrombocytopenia and its association with mortality in patients with COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[45]  C. Eastin,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The Journal of Emergency Medicine.

[46]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[47]  Xiaojuan He,et al.  Low Level Antibodies Against Alpha-Tropomyosin Are Associated With Increased Risk of Coronary Heart Disease , 2020, Frontiers in Pharmacology.

[48]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[49]  E. Dong,et al.  An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.

[50]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[51]  Daniel T. Montoro,et al.  A human ciliopathy reveals essential functions for NEK10 in airway mucociliary clearance , 2020, Nature Medicine.

[52]  Joel Nothman,et al.  SciPy 1.0-Fundamental Algorithms for Scientific Computing in Python , 2019, ArXiv.

[53]  M. Bronstein,et al.  Deciphering interaction fingerprints from protein molecular surfaces using geometric deep learning , 2019, Nature Methods.

[54]  B. Agrawal Heterologous Immunity: Role in Natural and Vaccine-Induced Resistance to Infections , 2019, Front. Immunol..

[55]  Alessandro Sette,et al.  The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..

[56]  J. Despotovic Emerging Therapies in Immune Thrombocytopenia , 2018 .

[57]  Y. Shoenfeld,et al.  Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction , 2018, Cellular & Molecular Immunology.

[58]  J. Kelton,et al.  Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia , 2016, British journal of haematology.

[59]  C. Pecquet,et al.  The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin , 2017, Front. Endocrinol..

[60]  Alexandre M. J. J. Bonvin,et al.  PRODIGY: a web server for predicting the binding affinity of protein-protein complexes , 2016, Bioinform..

[61]  Alexander D. MacKerell,et al.  CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field , 2015, Journal of chemical theory and computation.

[62]  Jiye Shi,et al.  SAbDab: the structural antibody database , 2013, Nucleic Acids Res..

[63]  S. Miller,et al.  Virus infection, antiviral immunity, and autoimmunity , 2013, Immunological reviews.

[64]  D. Kuter The biology of thrombopoietin and thrombopoietin receptor agonists , 2013, International Journal of Hematology.

[65]  S. Francis The role of cGMP-dependent protein kinase in controlling cardiomyocyte cGMP. , 2010, Circulation research.

[66]  J. Corbin,et al.  cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action , 2010, Pharmacological Reviews.

[67]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[68]  Geoffrey J. Barton,et al.  Jalview Version 2—a multiple sequence alignment editor and analysis workbench , 2009, Bioinform..

[69]  E. Birney,et al.  Pfam: the protein families database , 2013, Nucleic Acids Res..

[70]  Taehoon Kim,et al.  CHARMM‐GUI: A web‐based graphical user interface for CHARMM , 2008, J. Comput. Chem..

[71]  V. Georgiev,et al.  National Institute of Allergy and Infectious Diseases, NI , 2008 .

[72]  Leszek Rychlewski,et al.  The challenge of protein structure determination—lessons from structural genomics , 2007, Protein science : a publication of the Protein Society.

[73]  C. McCanny Lack of evidence , 2006, British Dental Journal.

[74]  F. W. Hoffbauer Liver disease , 2005, The American Journal of Digestive Diseases.

[75]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[76]  中島 務,et al.  マウス蝸牛における cyclic GMP-dependent protein kinase-I の発現 , 2005 .

[77]  J. Skolnick,et al.  TM-align: a protein structure alignment algorithm based on the TM-score , 2005, Nucleic acids research.

[78]  Takashi Kato,et al.  Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[79]  F. Hofmann,et al.  A Stimulatory Role for cGMP-Dependent Protein Kinase in Platelet Activation , 2003, Cell.

[80]  W. Gorczyca,et al.  [cGMP-dependent protein kinases]. , 2003, Postepy higieny i medycyny doswiadczalnej.

[81]  S. Lohmann,et al.  Cyclic GMP-dependent Protein Kinase Signaling Pathway Inhibits RhoA-induced Ca2+ Sensitization of Contraction in Vascular Smooth Muscle* , 2000, The Journal of Biological Chemistry.

[82]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[83]  H. Watarai,et al.  Neutralization of Biological Activity and Inhibition of Receptor Binding by Antibodies Against Human Thrombopoietin , 1998, Stem cells.

[84]  W R Taylor,et al.  Residual colours: a proposal for aminochromography. , 1997, Protein engineering.

[85]  M. Sanner,et al.  Reduced surface: an efficient way to compute molecular surfaces. , 1996, Biopolymers.

[86]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[87]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[88]  S. Nosé,et al.  Constant pressure molecular dynamics for molecular systems , 1983 .

[89]  A. Chobanian,et al.  Cardiovascular Complications , 2007 .

[90]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[91]  A. Szent-Györgyi Calcium regulation of muscle contraction. , 1975, Biophysical journal.